Context Therapeutics (NASDAQ:CNTX) Shares Down 6.4%

Context Therapeutics Inc. (NASDAQ:CNTX) shares traded down 6.4% on Friday . The stock traded as low as $1.32 and last traded at $1.32. 5,702 shares traded hands during mid-day trading, a decline of 89% from the average session volume of 53,032 shares. The stock had previously closed at $1.41.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright decreased their price target on shares of Context Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, March 21st.

Context Therapeutics Stock Down 6.4 %

The firm’s 50 day simple moving average is $1.22 and its two-hundred day simple moving average is $1.12.

Context Therapeutics (NASDAQ:CNTX) last posted its earnings results on Thursday, March 21st. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.07). On average, equities research analysts predict that Context Therapeutics Inc. will post -1.38 EPS for the current year.

Institutional Investors Weigh In On Context Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC increased its position in shares of Context Therapeutics by 47.4% during the second quarter. Renaissance Technologies LLC now owns 28,300 shares of the company’s stock worth $45,000 after acquiring an additional 9,100 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Context Therapeutics by 1.9% during the third quarter. Vanguard Group Inc. now owns 640,699 shares of the company’s stock worth $711,000 after acquiring an additional 11,720 shares in the last quarter. State Street Corp increased its position in shares of Context Therapeutics by 79.8% during the third quarter. State Street Corp now owns 32,907 shares of the company’s stock worth $37,000 after acquiring an additional 14,607 shares in the last quarter. Northern Trust Corp bought a new stake in shares of Context Therapeutics during the second quarter worth about $49,000. Finally, Atria Wealth Solutions Inc. bought a new stake in shares of Context Therapeutics during the second quarter worth about $51,000. 14.03% of the stock is owned by institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.